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Abstract
Nutrition plays an important role in osteoporosis prevention and treatment. Substantial progress in both laboratory analyses and clinical use
of biochemical markers has modified the strategy of anti-osteoporotic drug development. The present review examines the use of bio-
chemical markers in clinical research aimed at characterising the influence of foods or nutrients on bone metabolism. The two types of
markers are: (i) specific hormonal factors related to bone; and (ii) bone turnover markers (BTM) that reflect bone cell metabolism. Of
the former, vitamin D metabolites, parathyroid hormone, and insulin-like growth factor-I indicate responses to variations in the supply
of bone-related nutrients, such as vitamin D, Ca, inorganic phosphate and protein. Thus modification in bone remodelling, the key process
upon which both pharmaceutical agents and nutrients exert their anti-catabolic or anabolic actions, is revealed. Circulating BTM reflect
either osteoclastic resorption or osteoblastic formation. Intervention with pharmacological agents showed that early changes in BTM
predicted bone loss and subsequent osteoporotic fracture risk. New trials have documented the influence of nutrition on bone-tropic
hormonal factors and BTM in adults, including situations of body-weight change, such as anorexia nervosa, and weight loss by obese
subjects. In osteoporosis-prevention studies involving dietary manipulation, randomised cross-over trials are best suited to evaluate influ-
ences on bone metabolism, and insight into effects on bone metabolism may be gained within a relatively short time when biochemical
markers are monitored.
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Introduction
The aim of the present report is to review how biochemical
markers can be used to evaluate the potential benefit of
foods or nutrients on adult bone health and in primary
and secondary osteoporosis prevention. Nutrition and
physical activity are key behavioural determinants of the
development and progression of several chronic diseases,
including osteoporosis. In primary prevention, nutrition
combined with moderate physical activity plays an
important role in attenuating age-related bone loss. In
secondary prevention, adequate nutrition is adjuvant to
specific anti-osteoporotic medications, thus enabling their
full therapeutic effects.
This review focuses on the clinical application of
biochemical analyses that can respond to nutritional
interventions aimed at either preserving bone integrity or
attenuating bone loss in adults.
Effects of foods and nutrients on Ca and inorganic phos-
phate (Pi) economy(1) can be measured using bone-related
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circulating hormonal markers, such as vitamin D meta-
bolites(2), parathyroid hormone (PTH)(3,4) and insulin-like
growth factor (IGF)-I(5), as well as bone turnover markers
(BTM) that reflect bone formation and resorption(6–9).
New findings on BTM have improved how they are
viewed in the design, follow-up and interpretation of
clinical trial outcomes, particularly in postmenopausal
women and the elderly(8,9). Indeed, BTM changes can pre-
dict the later influence of pharmaceutical agents on bone
mineral density (BMD)/content and fragility fractures(6–9).
This will be discussed in the context of bone health-related
claims as they relate to evidence-based knowledge of nutri-
tional benefits. Examples of clinical trials are presented that
document how nutrients influence bone-trophic hormones
and biochemical markers of bone remodelling. Finally,
appropriate study designs using both biochemical markers
and new tools for assessing bone structure and function, as
well as biomechanical properties, will be discussed, taking
into account distinct adult populations.
Osteoporosis, a major health problem
Osteoporosis is a systemic skeletal disease characterised by
low bone mass and micro-architectural deterioration of
bone tissue with a consequent increase in bone fragility
and susceptibility to fracture that worsens with ageing(10).
Osteoporosis causes more than 8·9 million fractures
annually worldwide(10). The lifetime risk for wrist, hip or
vertebral fracture is estimated to be 30 to 40 % in devel-
oped countries. Epidemiological studies in both the USA
and UK indicate that one in two women aged 50 years or
older will have an osteoporotic fracture in their remaining
life; for men it is one in five(11). The most serious
osteoporotic fracture, at the proximal femur, typically
results when subjects having an intrinsic bone fragility
caused by both reduced mineral density and impaired
structural design have fallen. These fractures show an
exponential age-related increase and have a severe detri-
mental effect on the health of elderly populations(10,11).
Fragility fractures in elderly individuals are the long-term
pathological consequence of an imbalance between
bone resorption and bone formation leading to bone loss
with micro-structural alterations of both cortical and
trabecular structures(10,11).
Therapeutic options and limitations
There are many efficacious pharmaceutical options
that have been shown, in large and well-designed
randomised controlled trials (RCT), to significantly
reduce the risk of fracture in postmenopausal women
and the elderly(12,13). Nevertheless, insufficient compliance
in terms of both adherence and persistence to drug
prescription limits their effectiveness for the management
of individual patients in the real-world conditions of
medical practice(14–17).
It is relevant to note that in the stepwise drug develop-
ment phases, virtually all testing of major anti-osteoporotic
medications relied on BTM measurement to assess
efficacy.
Evidence-based criteria in osteoporosis management
Clinical evidence arises from the analysis of various
research approaches with the aim of proposing the
most reliable recommendations for practical disease man-
agement. The RCT is at the top of the strength-of-evidence
hierarchy. These RCT usually measure non-vertebral frac-
tures, and require that thousands of patients be followed
for at least 3 years to reach a sufficient statistical power.
However, some well-designed RCT testing specific
pharmaceutical agents in postmenopausal women have
failed to demonstrate efficacy for preventing hip frac-
ture(12). The incidence of hip fracture depends not only
on the drug efficacy for improving bone structure and
metabolism, but also on extra-skeletal factors, mainly
those related to the occurrence and circumstances of fall-
ing. This makes hip fracture a stochastic event, largely
independent of bone-active medications. Furthermore,
RCT for osteoporosis typically provide both treatment
and placebo groups with sufficient Ca and vitamin D,
which may have independent benefits on bone metab-
olism and attenuate the potential effect size on hip fracture
reduction.
Concept of evidence-based nutrition in bone health and
osteoporosis
Clinical research related to the impact of foods and/or
nutrients on bone metabolism and structure is hampered
by the difficulty to reach a level of evidence(18,19) similar
to that required of clinical trials that test pharmaceutical
drugs for osteoporosis management(20–22). It is difficult to
prove the efficacy of drugs for preventing fragility fracture
using large RCT designed for this purpose (see below), but
it is even more challenging to use the RCT approach to
evaluate whether foods or nutrients can reduce the risk
of fragility fracture(18,19). There is a major difference in
the level of strength evidence required for foods or nutri-
ents as compared with drugs, to evaluate not only benefits
but also risks(23–26). As explicitly stated by Heaney &
Blumberg, ‘. . .we cannot get RCT-level evidence from many,
and perhaps most, nutritional questions. . .’(25). Therapeutic
decisions using anti-osteoporotic drugs require evidence
based on high-quality RCT that have as their main outcome
the reduction of fragility fractures(20). Inferences are wea-
kened when studies rely on surrogate endpoints such as
BMD or BTM(20). Testing the efficacy of a food or nutrient
with the reduction of hip fracture risk as the main outcome
will probably never be amenable to RCT because it
would require that thousands of patients remain com-
pliant to the intervention for at least 3 to 4 years(18,19,23).
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Industry is unlikely to sponsor these large RCT because, in
contrast to drugs, marketing the products is not dependent
on the results of RCT. However, as compared with foods
or nutrients, the risk:benefit ratio is much greater with
drugs, as they may cause more severe adverse side
effects(18,19,24,25).
In the nutrition field, valuable information could be
obtained from RCT that have BTM endpoints reflecting
bone metabolism. The change in BTM can be detected
at a shorter time than the time for assessing effects on
fragility fracture rate. The validity of results obtained
from short-term RCT is strengthened by preclinical
studies carried out in reliable animal models of human
osteoporosis(27–31). The next sections will deal with the
scientific basis underlying these concepts.
Bone-related biomarkers: biochemical analyses and
clinical application
Both hormonal factors and biomarkers of bone remodel-
ling can be useful to assess the baseline status and the
response to an intervention in the context of prevention
or treatment of osteoporosis.
Bone mass can be estimated by measuring BMD, i.e.
areal BMD (aBMD) using dual-energy X-ray absorptiome-
try (DXA). While low aBMD is an important determinant
of fracture risk, its measurement does not capture all the
risk factors for fracture(32). In fact, up to half of patients
with incident fractures have baseline spinal or hip aBMD
assessed by DXA above the diagnostic threshold of osteo-
porosis defined as a T-score of 22·5 SD or more below the
average value of young healthy adults (i.e. WHO definition
of osteoporosis)(33,34). Using peripheral measurement
devices, 82 % of postmenopausal women with fracture
had T scores better than 22·5(35). Furthermore, there is
increasing evidence that the decision to use pharmacologi-
cal intervention for the prevention of fracture should be
based on the fracture probability rather than only on the
presence of osteoporosis as defined by aBMD T-score(32).
Therefore, in selecting patients for treatment, the risk of
fracture in individual subjects is now calculated by the
use of algorithms which include a number of recognised
independent risk factors for fracture in addition to aBMD,
such as age, sex, BMI, family history, past history of
fracture, secondary causes of osteoporosis such as rheuma-
toid arthritis, use of medications such as glucocorticoids,
smoking and excessive alcohol intake(32). FRAXw (WHO
Fracture Risk Assessment Tool) is such a fracture risk
calculator for the next 10 years (www.shef.ac.uk/FRAX/).
Bone-related circulating hormonal factors
Hormonal changes to insufficient supply of calcium,
vitamin D and protein. The main consequence of vitamin
D insufficiency, as expressed by a low circulating level of
25-hydroxyvitamin D (25(OH)D), is a decrease in the
intestinal absorption of both Ca and Pi. The reduction in
the supply of Ca from the intestinal tract leads to an
increase in the production of PTH to, at least partially,
compensate for hypocalcaemia by stimulating both
tubular Ca reabsorption and osteoclastic bone resorption.
The secondary hyperparathyroidism also contributes to
the associated hypophosphataemia resulting from the
reduced tubular Pi reabsorption.
When associated with a deficiency of protein, as
expressed by a low serum level of the anabolic agent
IGF-I, osteoblastic bone formation rate no longer is
matched to osteoclastic bone resorption rate. Moreover,
insufficient dietary protein, in concert with insufficient
vitamin D status, results in low intestinal Ca absorption.
At the kidney, the reabsorption of Pi and the synthesis of the
active metabolite of vitamin D, 1,25-dihydroxyvitamin D,
tend also to be depressed. Overall, the insufficient
dietary supply of these bone-trophic nutrients leads to
an uncoupling between the resorption and the formation
rate of the bone mineralised organic matrix that favours
resorption. Intermediate and long-term possible conse-
quences are measurable bone loss, by DXA or by
high-resolution peripheral computed tomography(36) and
increased risk of fragility fracture.
In the course of dietary interventions aimed at correcting
these nutrient insufficiencies, reliable biochemical assays
are available to monitor changes in serum levels of
25(OH)D, PTH and IGF-I. In order to link these hormonal
changes to the response of bone metabolism, BTM can
concurrently be measured during the dietary intervention
trial (see below).
Biochemical determination of bone-trophic hormonal
factors: parathyroid hormone. A recommendation has
been made to establish reference ranges for serum PTH
in vitamin D-replete healthy individuals(37), and to measure
PTH in postmenopausal osteoporotic women to exclude
secondary osteoporosis due to primary hyperparathyroid-
ism(3,38). Further, secondary hyperparathyroidism resulting
from inadequate Ca intake and/or vitamin D deficiency,
leading to an increase in bone resorption, is thus an
important determinant of hip fractures in the elderly(39–41).
It has been shown by several investigators that acute
oral Ca load or longer-term Ca supplementation (i.e. forti-
fied dairy products) have favourable effects on bone
metabolism by decreasing PTH and bone resorption
markers(42,43).
Biochemical determination of bone-trophic hormonal
factors: 25-hydroxyvitamin D. The measurement of
serum 25(OH)D is the best assessment of vitamin D
status. The level associated with optimal suppression of cir-
culating PTH levels has been used to define criteria for
vitamin D insufficiency, because of the inverse relationship
between serum 25(OH)D and PTH. However, this relation-
ship may be influenced by age, Ca intake, physical inactiv-
ity, renal function, ethnicity and other factors. Furthermore,
the use of different assays for 25(OH)D and PTH(44,45)
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may also influence the apparent threshold of 25(OH)D
concentration at which secondary hyperparathyroidism
occurs. Conservatively, a 25(OH)D level of 50 nmol/l
(20 ng/ml) is considered as vitamin D sufficient, represent-
ing a level above which there is no further suppression of
PTH, not much further reduction in BTM, and not much
further improvement of muscle function(46). The Institute
of Medicine also considers that serum levels of vitamin D
above 50 nmol/l are the level that is needed for good
bone health for practically all individuals, and set
a recommended daily intake of 600 IU/d for children and
adults and 800 IU for women and men 71 years or older
based on this cut-off(47). However, more recently, the clini-
cal practice guidelines of the Endocrine Society defined
vitamin D deficiency as 25(OH)D levels below 50 nmol/l
(20 ng/ml) and vitamin D sufficiency as 25(OH)D levels
greater than 75 nmol/l (30 ng/ml)(48). In a cross-sectional
analysis (National Health and Nutrition Survey (NHANES)
2003–2006) in the US population, maximum PTH
suppression expected to occur when vitamin D is suffi-
cient, corresponding to the zero slope between 25(OH)D
and PTH, did not occur until a serum 25(OH)D level of
approximately 100–125 nmol/l (40–50 ng/ml)(49). Debate
about the optimal vitamin D status continues(49–51).
There is evidence that Ca in combination with vitamin D
supplementation reduces the risk of fracture(52–55), bone
loss(56) and non-vertebral fracture risk(52); these effects
are more efficacious at 800 IU/d (20 mg/d) than 400 IU/d
(10 mg/d).
Biochemical determination of bone-trophic hormonal
factors: insulin-like growth factor-I. Measurement of
serum IGF-I is an important tool with growth hormone
(GH) not only in the diagnosis of various stature
disorders(57), but also as a nutritional marker, particularly
of protein intake(58,59). IGF-I and GH are regulators of
bone homeostasis and are important for the acquisition
of bone mass during adolescence, for the achievement of
peak bone mass and for the maintenance of skeletal archi-
tecture during adult life(60,61). Although GH may act directly
on skeletal cells, most of its effects are mediated by IGF-I,
which is present in the systemic circulation. Systemic
IGF-I is synthesised in the liver under the influence of
GH. IGF-I is also produced by a variety of cell types and
acts in a paracrine fashion in many tissues. Availability of
IGF-I is regulated by IGF binding proteins (IGFBP). Serum
IGF-I levels are associated with bone mass. IGF-I levels
peak at puberty when bone acquisition is maximal but
levels of GH, IGF-I, and some IGFBP that regulate IGF
activity decrease with age(61–63). This decline in GH and
IGF-I secretion has been correlated with bone loss in
postmenopausal women. A relationship between IGF-I
levels and fracture risk has also been reported(64,65). How-
ever, it is not entirely clear how IGF-I is involved in the
pathogenesis of osteoporosis, as serum IGF-I levels are
strongly influenced by catabolic states, undernutrition and
advanced age, all factors that increase the risk for fracture.
Dietary proteins influence both the production and
action of IGF-I. Protein restriction is associated with
reduced IGF-I levels by inducing a resistance to the GH
action in the liver, and by an increased IGF-I metabolism.
Decreased IGF-I levels are observed in states of under-
nutrition (i.e. also in anorexia nervosa). On the other
hand, increased protein intake can prevent the decrease
in IGF-I in hypoenergetic states. Experimental and clinical
observational data suggest that IGF-I plays an important
role in the pathophysiology of osteoporosis, osteoporotic
fractures and its complications. Correcting altered IGF-I
in the elderly by protein replenishment may favourably
influence not only bone mass, but also muscle mass and
strength that are important determinants for the risk of
falls. The changes of IGF-I levels in nutrition-related
changes in body weight are described below.
Bone turnover markers
Importance of bone remodelling in osteoporosis. Bone
remodelling is an important process that continuously
renews the cortical and trabecular envelopes throughout
life. It repairs micro-damage, maintains mineral homeo-
stasis and ensures mechanical competence by modifying
the micro-architecture. Bone remodelling is regulated
by a variety of systemic and local factors as well as by
nutritional factors (Fig. 1). Bone remodelling follows a
sequence of events that includes activation, recruitment
of osteoclasts to begin resorption, degradation and
removal of bone, reversal, and formation of new bone by
osteoblasts (Fig. 1). After this phase, a quiescent or resting
period occurs. Remodelling begins with release of cyto-
kines from osteoblast precursors, leading to recruitment
of osteoclast precursors, which differentiate in multinu-
cleated osteoclasts and subsequently attach to the bone
surface. Resorption of the skeletal matrix releases growth
factors such as IGF-I and transforming growth factor-b,
which recruit lining cells and early osteoblast precursors
that eventually form new bone (Fig. 1). Osteoblasts that
do not undergo apoptosis remain on the bone surface as
lining cells or become entrapped as osteocytes into the
new bone matrix. These osteocytes respond to gravita-
tional forces and can signal to lining cells to initiate
remodelling. Antiresorptive and anabolic agents influence
bone structure by affecting remodelling. Likewise, supply
in Ca, vitamin D and protein influences bone remodelling.
The presence of Ca and vitamin D inhibits bone resorption,
and protein stimulates bone formation (Fig. 1). Ca, Pi and
vitamin D are necessary for adequate mineralisation of the
newly formed bone matrix (Fig. 1).
In young adulthood, the amount of bone removed by
the osteoclasts is equal to the amount of bone formed
by the osteoblasts, so that bone mass is maintained. After
the menopause and with ageing in both sexes, there is a
progressive bone loss due to an imbalance between
bone resorption and formation.
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There is a substantial body of evidence that accelerated
bone turnover is associated with a higher risk of fracture,
independent of other parameters such as age or BMD
(see below). BTM are not included in the fracture risk
calculator (FRAXw), mainly for the reason that their
relationships with other established risk factors included
in the risk calculator are not clarified and because different
markers and different methodologies for their assessment
have been used across studies. This has led to the
recommendation for the standardisation of BTM measure-
ments in future studies and it is suggested that serum
carboxy terminal telopeptide of collagen type I (s-CTX) is
used as the reference bone resorption marker and
serum procollagen type I N-terminal propeptide (sPINP)
as the reference bone formation marker, measured by
standardised assays(66).
Bone markers reflecting bone formation and bone
resorption
The BTM can be divided into two groups: markers of
resorption and markers of formation (Fig. 2). The principal,
specific markers of bone formation, measured in serum by
immunoassays, are bone alkaline phosphatase (BAP),
osteocalcin (OC) and PINP. Most assays are now adapted
to automated platforms(7) (Fig. 2). Markers of bone
resorption are the pyridinium cross-links (pyridinoline
and deoxypyridinoline) and their associated peptides
(telopeptides), released during collagen breakdown(6).
Markers of osteoclast number include tartrate-resistant
acid phosphatase isoenzyme 5b (TRAP 5b), the osteo-
clast-specific isoform of total TRAP, and, potentially,
cathepsin K (Fig. 2). These enzymes are expressed and
released by osteoclasts(67). TRAP 5b is the most commonly
used marker of osteoclast number.
Ca, phosphate,
vitamin D
Mineralisation
Anabolic agents
proteins Ob
Quiescence
Reversal
LC
Oc
Ocl
Ocl apoptosis
Activation
Antiresorptive agents
Ca and vitamin D
Formation
 about 150 d
About
200 d
Resorption
about 20 d
Fig. 1. Bone remodelling cycle. Bone turnover follows a sequence of events that includes activation, recruitment of osteoclasts (Ocl) to begin resorption,
degradation and removal of bone, reversal, and formation of new bone by osteoblasts (Ob). After this phase a quiescent or resting period occurs. LC, lining cell;
Oc, osteocyte.
Pyridium cross-links
Collagen type l
telopeptides (CTX, NTX)
Osteoclast
Osteoblast
Osteoclacin
Osteoid
Collagen type l
propetides
BAP
Bone matrix
TRAP
Resorption Formation
Fig. 2. Diagram of the relationship between bone resorption or formation and
bone turnover markers. On the resorption side, tartrate-resistant acid phos-
phatase (TRAP) reflects osteoclast number and activity, whereas pyridium
cross-links, carboxy terminal telopeptide (CTX) and N-terminal telopeptide
(NTX) are markers of bone matrix resorption. On the formation side, collagen
type I propeptides, such as procollagen type I N-terminal propeptide (PINP),
bone alkaline phosphatase (BAP) and osteocalcin reflect mainly osteoblastic
bone formation. Osteoid corresponds to the non-mineralised bone matrix.
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TRAP 5b is predominantly expressed by osteoclasts, and
immunoassays to detect this isoform have been deve-
loped(68–70). In absolute terms, the response of TRAP 5b
to antiresorptive therapy is not as great as the response
of s-CTX, but within-subject variability is significantly
lower. TRAP 5b has a lower diurnal variability than
s-CTX and lower acute effect of feeding, possibly due to
a longer circulating half-life, making it less susceptible to
short-term influences(71). Furthermore, TRAP 5b is not
cleared by the kidney, and thus does not accumulate in
renal failure(69,71).
Predictive value of early changes in bone markers in
response to pharmaceutical agents on later effects on
bone mineral density/content and fragility fractures:
bone turnover markers and the rate of bone loss. There
is evidence that bone turnover increases rapidly after
menopause and persists for up to 40 years(72,73). In post-
menopausal women bone turnover rate accounts for
.50 % of the variation in bone mass, whereas in premeno-
pausal women it is 0–10 %(74,75).
Several prospective studies have demonstrated corre-
lations between levels of BTM and rates of bone loss
assessed by serial measurement of aBMD or bone mineral
content at different skeletal sites over a time period span-
ning 13 years(76). These studies support an inverse relation-
ship between BTM and aBMD. This inverse relationship
becomes stronger with advancing age and the relationship
is significantly stronger for resorption markers than for
formation markers, due to the fact that the increase of
bone resorption with ageing is greater than the increase
in bone formation(77). However, this inverse correlation
between BTM and aBMD does not seem to apply to all
skeletal sites. A significant correlation between the rate of
turnover and rate of bone loss at the hip or radius has
been demonstrated in postmenopausal women, but not
for the bone loss at the spine(78,79). Extra-skeletal calcifica-
tion and/or compression fracture occurring with advancing
age can overestimate aBMD measurements at the spine.
There is also evidence indicating that bone resorption mar-
kers can detect ‘rapid losers’ (.3 % loss in aBMD per year)
in a follow-up period of 2–12 years(80–82). At the present
time a single measurement of a biochemical marker
cannot predict the absolute rate of bone loss in a single
individual. However, increased BTM can be regarded as
a risk factor for rapid bone loss.
Predictive value of early changes in bone markers in
response to pharmaceutical agents on later effects on
bone mineral density/content and fragility fractures:
bone turnover markers and fracture risk. BTM may be
useful in the assessment of fracture risk. Findings of
prospective studies have shown that BTM of resorption
predict fracture risk in postmenopausal women and in
men (Table 1)(74,83–89). In five prospective studies of post-
menopausal women (Epidemiology of Osteoporosis
(EPIDOS), Rotterdam, Os de Femmes de Lyon (OFELY),
Hawaii Osteoporosis Study (HOS), and Malmo¨ Osteoporo-
sis Prospective Risk Assessment (OPRA)), there were
significant associations of baseline levels of urinary or
s-CTX, urinary free deoxypyridinoline, or serum TRAP 5b
with fracture risk(74,83–87) (Table 1). An increase of these
markers above the premenopausal range was associated,
after adjustment for aBMD, with a twofold increase in
risk for hip, vertebral and non-vertebral fractures, over a
follow-up period of 1.8 to 5 years. The results for the
relationship between bone formation markers and fracture
risk are not consistent. In the French cohort study of
elderly women (EPIDOS), no significant relationship
between OC or BAP and fracture risk could be demon-
strated during a 2-year follow-up. In contrast, in younger
healthy postmenopausal women (OFELY and HOS
cohorts), a significant association was found between
increased BAP serum levels and risk of vertebral as well
as non-vertebral fracture(74,83,84).
These results suggest that a combined approach, with
both aBMD and indices of bone turnover, could improve
fracture prediction in postmenopausal women. In fact, cal-
culating the absolute risk of fracture by combining clinical
risk factor (i.e. previous fracture), low aBMD and increased
bone turnover (high CTX) resulted in a better hip fracture
probability at 10 years than with low aBMD alone(90). In
elderly men high bone resorption was also associated
with an increased risk of osteoporotic fracture(87).
Table 1. Relationship between increases in bone resorption rate and fracture risk
Study Age (years) Fracture RR-BMD* 95 % CI Marker RR-marker† 95 % CI
Women EPIDOS(74) .75 Hip 2·8 1·6, 5·1 Urinary CTX 2·2 1·3, 3·6
OFELY(83) 64 (mean) All 2·8 1·4, 5·6 Urinary CTX 2·3 1·3, 4·1
Serum CTX 2·1 1·1, 3·6
HOS(84) 69 (mean) All 1·6 1·2, 2·2 Urinary CTX 1·6 1·2, 2·0
Rotterdam(85) .75 All 1·3 0·6, 2·8 Urinary DPD 1·9 1·2, 3·8
Malmo¨ OPRA(86) .75 All 2·2 1·5, 3·1 TRAP 2·2 1·2, 4·2
Men DOES(87) 72 (mean) All 1·8 1·4, 2·3 ICTP 1·4 1·0, 1·9
2·8‡ 1·4, 5·4
RR, relative risk; BMD, bone mineral density; EPIDOS, Epidemiology of Osteoporosis; CTX, carboxy terminal telopeptide of collagen type I; OFELY, Os de
Femmes de Lyon; HOS, Hawaii Osteoporosis Study; DPD, free deoxypyridinoline; OPRA, Osteoporosis Prospective Risk Assessment; TRAP, tartrate-
resistant acid phosphatase; DOES, Dubbo Osteoporosis Epidemiology Study; ICTP, C-terminal telopeptide generated by metalloproteinases.
* RR-BMD ¼ RR for fracture by 1 SD decrease in BMD.
† RR-marker ¼ RR for fracture by 1 SD increase in marker above the premenopausal normal range.
‡ For the highest quintile.
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Bone turnover markers and treatment monitoring. The
main domain for the clinical use of BTM is the monitoring
of osteoporosis therapy. The ultimate goal in treating
patients with osteoporosis is to reduce their fracture
risk. However, the short-term incidence of osteoporotic
fractures is low, and the absence of fracture during
treatment does not necessarily mean that the treatment is
effective. Consequently, serial measurements of changes
in aBMD as a surrogate marker of therapeutic efficacy are
currently the standard approach to monitor osteoporosis
therapy. Yet, changes in aBMD occur slowly and thera-
peutic effects are usually not detectable before 1–2 or
more years of treatment(80,91–94). In contrast, BTM levels
change much faster than aBMD in response to therapeutic
interventions(80). Antiresorptive treatment generates a rapid
decrease in bone resorption markers after only 2–4 weeks,
reaching a plateau after 3 to 6 months of treatment(80,95)
(Fig. 3(a)). The decrease in bone formation markers,
reflecting the physiological coupling of bone formation
to bone resorption, is delayed and reaches a plateau after
6–12 months. The magnitude of the decreases varies
according to the type and dose of the drug and the
marker used to assess the effect (Table 2).
Evidence from interventional drug trials, where the
placebo groups received Ca and vitamin D, as well as in
nutritional interventions with fortified food, shows a
reduction in bone resorption markers of 20–30 % (as
outlined in more detail in the ‘Study designs to test the
effects of food products on bone metabolism’ section).
The decrease in BTM during antiresorptive treatment is
inversely related to the subsequent increase in aBMD,
predominantly at the lumbar spine(80,81). Several studies
of postmenopausal women treated with antiresorptive
agents (hormone replacement therapy, raloxifen, bispho-
sphonates) have indicated that the degree of short-term
reduction in BTM (after 3 to 6 months) correlates with
the observed long-term increase in aBMD after 1 to 3
years of treatment(79,81,95–99). Reduction in fracture risk is
only partially explained by the documented changes in
aBMD (4–28 %)(91,100–104). There is also some evidence
that even a modest decrease in bone mass is nevertheless
associated with some fracture risk reduction(105). There is
thus substantial evidence that bone mass or changes
thereof does not explain satisfactorily either the skeletal
fragility of osteoporosis or the effects of bone active
agents(106). It is therefore possible that changes in
other determinants of bone strength, including the rate of
bone turnover, may be more predictive of anti-fracture
efficacy than changes in aBMD. In fact, several studies
confirmed that short-term reductions in bone turnover
were associated with a reduction in vertebral and/or
non-vertebral fracture risk in women treated with
hormone replacement therapy, raloxifene, risedronate
and alendronate(88,102,107–109).
In contrast to antiresorptive agents, PTH fragments
administered intermittently in low doses increase bone
remodelling, stimulating bone formation preferentially
over bone resorption, and resulting in net gain of bone
and reducing fracture risk(110–112). Increases in BTM indi-
cate a skeletal response to PTH. There is evidence that
early measurement of bone formation markers (OC, BAP
and particularly PINP) correlates positively with the sub-
sequent BMD response to PTH (Fig. 3(b))(113–116). These
data suggest that serial BTM measurements could become
useful in identifying skeletal responders to an anabolic
therapy with PTH. Based on results from clinical studies
and improved technical performance on automated
platforms, several national and international guidelines
recommend these markers in the follow-up of patients
treated for postmenopausal osteoporosis(32,117,118).
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Fig. 3. Schematic representation of changes in bone turnover markers
(BTM) at 3–6 months and corresponding increase in bone mineral density
(BMD) during treatment of osteoporosis. (a) Bone antiresorptive treatment
(i.e. bisphosphonate): a more pronounced decrease in bone resorption
marker at 3–6 months is associated with larger increases in BMD. (b) Bone
formation-stimulating treatment (i.e. recombinant parathyroid hormone): a
greater increase in bone formation marker is associated with a larger
increase in BMD. * Mild response in changes in BTM and BMD. † Moderate
response in changes in BTM and BMD. ‡ Pronounced response in changes
in BTM and BMD. The diagrams show the relationship between early
changes (3–6 months) in BTM and changes in BMD after 2 years of either
bone resorption inhibition (a) or bone formation stimulation (b). Fig. 3(a) is
based on quantitative data obtained by antiresorptive treatment with alendro-
nate, documenting tertile changes at 6 months of the bone resorption marker
urinary N-terminal telopeptide (u-NTX) and the changes in BMD as assessed
by dual-energy X-ray absorptiometry (DXA) in total hip, trochanter and spine
at 3 years in postmenopausal women(98). Fig. 3(b) is based on quantitative
data obtained by anabolic treatment with parathyroid hormone documenting
tertile changes at 3 months of the bone formation marker N-terminal procolla-
gen I propeptide (PINP) and the change in areal and volumetric BMD at
12 months, as assessed in the spine by DXA and quantitative computed
tomography in postmenopausal women(98,113).
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Usefulness of biomarkers of bone turnover in clinical
nutrition research
In the process of generating scientific support for claims on
foods, BTM were deemed as not sufficiently indicative of
bone health to provide evidence for enhanced function
or reduced osteoporosis risk(29). However, over the last
10 years there have been improvements in analytical
performance and new knowledge of how biochemical
markers can be of great utility in osteoporosis manage-
ment. Because BTM measurement can assess response to
anti-osteoporotic medications, the time has come to use
BTM levels to reflect bone formation and resorption in
response to foods and nutrients.
Influence of foods or nutrients on bone turnover markers
Several studies have examined the response of BTM levels
and related hormonal factors to varying food or nutrient
consumption in postmenopausal women or in elderly
individuals. These studies illustrate how BTM can be
important in establishing food and nutrient health claims.
Postmenopausal women
In a 12-month intervention involving postmenopausal
women (mean age 60–62 years), the consumption of Ca-
and vitamin D-fortified milk and yogurt favourably influ-
enced vitamin D status and bone metabolism, as expressed
by changes in serum 25(OH)D, PTH, CTX and IGF-I, as
compared with a control group maintaining their usual
diet or a group receiving equivalent Ca as lactate–gluco-
nate and bicarbonate salts(119) (Fig. 4). A prospective
cross-over trial in postmenopausal women (mean age 59
years) found that supplementation with non-fortified
milk for 6 weeks induced a decrease in serum PTH and
BTM, including CTX, and a non-significant increase in
IGF-I(120). In a randomised study of postmenopausal
women (mean age 57 years), consumption of a vitamin
D- and Ca-fortified soft white cheese significantly reduced
the sensitive biochemical marker of bone resorption TRAP
5b and increased serum IGF-I levels(121).
Elderly individuals
Favourable effects of milk, fortified or not with vitamin D
or Ca, on bone turnover in elderly individuals have been
documented in several intervention studies(42,120,122–124).
Interventions with dairy products such as yogurts(125,126)
or soft white cheese(126–128) have shown reductions in
bone turnover. In institutionalised elderly individuals with
vitamin D deficiency and secondary hyperparathyroidism,
an 8-week consumption of vitamin D- and Ca-fortified
yogurts saw increases in serum 25(OH)D, associated with
a reduction in the BTM CTX and TRAP 5b, and a normal-
isation of previously high serum PTH(126). Elderly patients
hospitalised for an osteoporotic fracture of the proximal
femur often present with signs of undernutrition, particu-
larly protein malnutrition(129). In a randomised study,
protein repletion by the daily consumption of a 20 g
casein-enriched food v. an isoenergetic non-protein sup-
plement led to a significant elevation in serum IGF-I by
the end of the 6-month dietary intervention(58). The
serum IGF-I response to 20 g/d protein repletion in
patients with a recent hip fracture was observable by 7 d,
with no further rise in serum IGF-I(130). Thus, in hip frac-
ture patients, the long-term effects of various protein prep-
arations on IGF-I can be predicted from changes observed
as early as 1 week following protein supplementation(130).
Bone turnover markers in clinical research on eating
disorders
Several nutrition-related disorders can lead to bone
loss and increased risk of osteoporotic fracture.
Table 2. Changes from baseline in serum tartrate-resistant acid phosphatase (s-TRAP), carboxy terminal telopeptide
of collagen type I (s-CTX) and procollagen type I N-terminal propetide (s-PINP) in response to antiresorptive and
bone formation-stimulating treatments*
Change from baseline (%)
Compound Dose and route of administration s-TRAP s-CTX s-PINP
Ca þ vitamin D 500–1000 mg þ10–20mg/d (p.o.) 220 to 225 220 to 230 210 to 220
Alendronate 70 mg/week (p.o.) 2 30 to 240 270 to 280 260 to 270
Risedronate 35 mg/week (p.o.) 250 to 260 240 to 250
Ibandronate 150 mg/month (p.o.)
3 mg/3 months (i.v.) 260 to 280 260 to 270
Zoledronate 5 mg/year (i.v.) 250 to 260 250 to 260
Raloxifene 60 mg/d (p.o.) 210 to 215 220 to 250 230 to 240
Denosumab 60 mg/6 months (s.c.) 270 to 290 260 to 270
PTH 1–34 (teriparatide) 20mg/d (s.c.) Up to 80 Up to 200
PTH 1–84 100mg/d (s.c.) 10–100 90–150
p.o., Oral; i.v., intravenous; s.c., subcutaneous; PTH, parathyroid hormone.
* Data have been adapted from the references Naylor & Eastell(8), Henriksen et al.(67) and Bonjour et al.(127).
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Their pathophysiology and clinical expression in relation
to the application of biochemical markers are relevant to
the present review.
Anorexia nervosa
In young women with anorexia nervosa, aBMD is reduced
at several skeletal sites(131). Body weight, but not oestrogen
use, is a significant predictor of aBMD in these patients.
Together with low endogenous oestrogen levels and Ca
deficiency, a low protein intake very probably also contrib-
utes to the bone deficit observed in anorexia nervosa.
However, low Ca intake has not been consistently reported
and 25(OH)D serum levels are usually normal(132). The
BTM of bone formation, serum OC and BAP, are signifi-
cantly reduced in adolescents whereas in adults with anor-
exia nervosa, the markers of bone resorption are elevated
while those of formation are suppressed(133,134). The serum
level of IGF-I is low in anorexia nervosa(135,136), an obser-
vation quite compatible with insufficient protein intake(135)
although low protein intake has not been consistently
recorded. Nutritional rehabilitation reversed the uncou-
pling of bone remodelling(137) and led to a significant
increase in BTM of formation followed by increases in
aBMD in as little as 3 months(134). This reversibility
occurs before oestrogen levels rise and menses return,
suggesting that nutritional factors are of paramount
importance(132,134).
The serum level of IGF-I was reported to increase
rapidly after the onset of intravenous hyperalimentation,
followed by a progressive elevation in serum osteo-
calcin(136). IGF-I level changes were dependent on
variations in the nutritional state(133). Increased GH levels
accompanied by decreased IGF-I are seen in anorexia ner-
vosa, suggesting an acquired resistance to GH that reversed
with refeeding(132). The administration of recombinant
IGF-I alone has only a small bone-sparing effect(138). This
is not surprising, since the anabolic effects of IGI-I on
bone formation are tempered by poor nutrition, particu-
larly by insufficient protein intake(139).
Intensive exercise
In female athletes or ballet dancers, intensive exercise in
the absence of appropriate nutrition can lead to hypothala-
mic dysfunction with delayed menarche and disruption of
menstrual cyclicity, bone loss and increase risk of frac-
ture(140–142). Nutritional restriction, more common when
leanness confers advantages for performance, can play
an important role in the disturbance of the female repro-
ductive system when combined with intense physical
activity. Insufficient energy intake with respect to energy
expenditure impairs the secretion of gonadotropin-releas-
ing hormone and thereby leads to a state of hypo-oestro-
genism. This hormonal disturbance is reversed by
nutritional rehabilitation leading to an increase in both
luteinising hormone and follicle-stimulating hormone.
These changes occur well before oestrogen rises and
menses return, suggesting the dominant effect of nutri-
tional factors(132). However, the relative contribution of
insufficient protein intake with low IGF-I remains to be
assessed since it is often associated with reduced energy
intake. The consequence on bone metabolism of acute
experimental energy restriction has been investigated in
young exercising female volunteers(143). This study indi-
cated that severe reduction in energy availability rapidly
induces a negative uncoupling between bone formation
and bone resorption(143). The resulting bone loss may
become irreversible with persistence of such a negative
uncoupled remodelling, explaining the increased risk of
fragility fractures in anorexia nervosa(132,144) as well as in
certain athletes and ballet dancers(140,142).
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Fig. 4. Changes (%) in serum biochemical indexes at 5 months (a) and in bone mineral density (BMD) at 12 months (b) in response to fortified dairy products (B)
for 12 months as compared with controls (B) in postmenopausal women. Data are adapted from Manios et al.(119). PTH, parathyroid hormone; CTX, carboxy
terminal telopeptide of collagen type I; IGF-I, insulin-like growth factor-I. P ¼ Probability level for treatment £ time interaction effect as compared with the control
group.
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Induced weight loss in overweight/obese subjects
Reduction in energy balance induced by energy restriction
is often associated with bone loss that varies according to
sex, age, ovarian function and initial fat mass (for a
recent review, see Shapses & Sukumar(145)). The degree
of bone loss also depends upon the kind of diet accompa-
nying the energy restriction. Bone mineral loss during
body-weight reduction may not be fully recovered with
weight regained, at least in postmenopausal women(146).
Hence, it is important to understand the underlying patho-
physiological mechanisms and thereby define the best
strategies to prevent bone loss during energy restriction
in overweight/obese individuals. Several studies have
used bone health biomarkers, particularly with the objec-
tive to identify the key implicated nutrients.
Ca intake typically decreases with energy-restriction
diets. In this condition, the reduced Ca intake is associated
with elevation in both serum PTH and biochemical
markers of bone remodelling(147,148). Consumption of Ca
salt supplements can suppress the rise in both serum
PTH and BTM(147,149–151).
Dairy products may prevent bone loss during energy
restriction not only by providing Ca but also by supplying
proteins. Weight-reducing diets that are high in dairy pro-
ducts can suppress the rise in bone turnover and prevent
bone loss(152,153). In postmenopausal women, a random-
ised 12-month controlled study showed that higher dietary
protein intake (86 v. 60 g/d) during weight reduction
increased serum IGF-I and attenuated loss of aBMD at sev-
eral skeletal sites and volumetric BMD at the distal
tibia(154). The additional consumed proteins were from var-
ious food sources including dairy products, with a whey
supplement providing 6 g protein/d(154). Combining dairy
foods with physical exercise(155,156) might be appropriate
to prevent bone loss during weight loss in overweight/
obese human adults(157). In a recent study, hypo-energetic
diets higher in dairy Ca and protein combined with daily
exercise favourably affected bone health biomarkers as
follows: decrease in PTH; increase in bone formation mar-
kers (OC and PINP) with no change in bone resorption
markers (CTX and N-terminal telopeptide (NTX)); incre-
ment in osteoprotegerin:receptor activator of NFkB ligand
(RANKL) ratio(157).
Study designs to test the effects of food products on bone
metabolism
In order to provide information on medical practice, the
needed evidence-based criteria differ for foods and nutri-
ents as compared with drugs. The development of drugs
requires a very high level of rigour, more for safety con-
cerns than for providing evidence of efficacy(18,24,25). The
present review essentially considers the rationale for
using BTM in clinical research on foods or nutrients that
influence bone mineral economy and/or metabolism.
Issues with randomised controlled trials in osteoporosis
An RCT is the clinical study design that best permits strong
causal inference between a tested drug or nutrient and a
given outcome(18,20). Previous reviews or position papers
have emphasised the distinct differences in the evidence
that can be obtained by using RCT in the context of drug
testing, as compared with the development of nutrient
requirement or dietary guidelines(18,23,24,158,159). In the
osteoporosis context, in order to demonstrate the efficacy
of a new medication, regulatory agencies usually require
RCT of 3 years’ duration, with fracture as the primary
endpoint. In the nutrition field, all types of research are
useful in setting dietary recommendations: observational
studies, to document prevalence and generate hypotheses;
preclinical experiments to identify physiological and
biochemical pathways; qualitative studies to understand
the human condition; and, finally, RCT, to establish a
relationship of causality(18,24,25,160).
Ethical consideration in randomised controlled trials and
sample size
The demonstration that a drug is efficacious for reducing
the burden of fragility fractures necessitates the design of
RCT with very large sample sizes. It is especially the case
when, for ethical reasons, the new therapy is tested in
so-called ‘active comparator trials’, i.e. when the recently
developed medication is compared with an approved
drug with convincing antifracture efficacy in patients at
high risk of fragility fractures(161). Moreover, a placebo-
controlled trial can neither be considered ethically accepta-
ble when the new drug is tested in patients at low risk of
fractures. This study design requires a much larger
number of subjects, as compared with previous RCT con-
ducted in patients at high risk of fragility fractures(161).
Thus, proper design and execution of long-duration large
RCT aimed at demonstrating the antifracture efficacy of a
drug impose requirements that are difficult to meet(158).
This difficulty also encompasses both the narrow response
due to the placebo effect and the non-random loss of
enrolled subjects that convert a randomised trial into a
cohort study(158). It can be expected to be magnified in
long-duration RCT aimed at testing the antifracture efficacy
of foods or nutrients in osteoporotic patients(18,158).
Surrogate endpoints for antifracture efficacy of new drugs
Therefore, the development of surrogate endpoints for
antifracture efficacy of new drugs has been considered
not only for foods and nutrients(158,159), but also for
drugs(161). Taking into account not only the large sample
size but also the very long duration of conducting RCT
with fragility fracture as the primary outcome, it is worth
considering the measurement of fracture-related data that
can be obtainable within a few weeks or months after
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the onset of the intervention. In clinical investigation, it is
recognised that the early bone remodelling response is
a good predictor of fragility fracture(158,159). Effective
pharmaceutical agents, whether acting via anticatabolic
or anabolic mechanisms, very promptly influence bone
remodelling, as biochemically expressed by measuring
BTM changes(158). These pharmoco-kinetic and -dynamic
characteristics, that combine an early response to interven-
tion with a reliable predictability of fragility fractures, make
BTM tools better suited to assess the effects of foods or
nutrients in clinical research on osteoporosis than the
delayed changes in DXA-measured aBMD or bone mineral
content. Furthermore, the effect size is usually larger with
BTM after a few months than the changes in BMD/bone
mineral content that can be observed after 1, or more
frequently, 2 years of intervention.
Short-duration randomised controlled trials in nutrition
clinical research
In adulthood, the effects of foods on BTM can be assessed
in appropriately designed RCT. Examples of such studies
are described in the ‘Study designs to test the effects of
food products on bone metabolism’ section. The short
duration of these RCT limits the number of non-compliant
participants. Furthermore, one may also expect that few
subjects will be completely lost, i.e. without outcome
measurement. This makes the ‘intention-to-treat’ data anal-
ysis more valuable for comparison with the ‘per protocol’
analysis that will only include treatment-adhering partici-
pants, and thereby provides an estimate of the effect size,
some sort of ‘dose–response’, of the intervention.
A physiologically meaningful set of biochemical vari-
ables can be selected and assessed at several time points.
For instance, when nutritional products are evaluated for
their capacity to improve vitamin D status and bone metab-
olism, changes in serum 25(OH)D, PTH, bone formation
and resorption markers should provide information on
the dynamic interrelationships between these variables.
Measuring the circulating level of IGF-I can assess the
response to an increase in protein intake. These short-
term RCT studies should provide not only qualitative infor-
mation on the response but also quantitative data on both
the magnitude and the pharmacokinetics of the effects.
The advantage of cross-over design in nutritional
investigation
A powerful methodology is the cross-over design, also
called ‘n of 1 RCT’(162,163). Herein there are two interven-
tion periods, separated by a ‘washout’ period, the duration
of which depends upon how long the effect of the inter-
vention lingers after its discontinuation. For some anti-
osteoporotic agents such as bisphosphonate compounds,
the effect can last months or years. For foods and nutrients
acting on bone, the effects may be ‘washed out’ much
more rapidly, i.e. within a few days or weeks, with the
exception of large doses of vitamin D. Within a trial,
each participant acts as his or her own control, and permits
comparison between and within groups(164). This design
eliminates any genetic influence and reduces bias associ-
ated with imbalance in known and unknown confounding
variables, as compared with randomised parallel-group
controlled trials enrolling two unrelated groups of
subjects(164).
Comparative effectiveness research
An important recent trend in medical research is to apply
‘comparative effectiveness research’ (CER)(165). CER is a
marked departure from the efficacy standard that any
new intervention should outperform placebo or random-
ised controls. There is particular emphasis placed on the
leading question regarding clinical effectiveness of care.
A CER study is aimed at determining the value of an inter-
vention over another. It answers two relevant questions:
(1) how effective is the intervention, if enrolled subjects
follow it as prescribed?; (2) how likely is it that the enrolled
participants follow it as prescribed?(166). In a classically
designed study, the answers to these two questions
would be given by comparing the results computed by
‘intention to treat’ with those analysed ‘per protocol’. CER
is a recommended priority for nutrition research(165).
Although CER will pose challenges for medical and nutri-
tional industries, it will present numerous opportunities
to improve the information base supporting nutritional
products, especially when they are integrated into other
medical interventions(166). Recent CER nutrition studies
have been reported on the bone effects of several
vitamin D and Ca supplement regimens(167,168).
Conclusions
Osteoporosis is a major health problem for an increasing
number of adults as they age. Nutrition plays a substantial
role in the primary and secondary prevention of osteo-
porosis. Several nutrients exert reproducible beneficial
effects on bone metabolism, reducing the acceleration of
bone loss that occurs after the menopause and in the
elderly. The supply in vitamin D, Ca, Pi and protein affects
levels of bone-trophic hormones as well as resorption of
the bony organic matrix and its subsequent formation
and mineral deposition. Some foods and nutrients posi-
tively influence bone metabolism by either reducing
bone resorption or increasing bone formation, or both.
Measurement of several biochemical components in
blood facilitate the delineation of the impact of nutrients
and food factors on bone-trophic hormones such as
vitamin D metabolites, PTH and IGF-I, and on BTM that
reflect bone resorption and/or matrix formation and miner-
alisation. Cross-over randomised trials appear to be the
optimal way to evaluate the influence of nutrients and
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food factors on bone metabolism. Using such a study
design, which is considered near the top of the hierarchy
of evidence for nutritional studies, biologically significant
insight can be gained into the potential influence of food
products on bone metabolism and osteoporosis prevention
within a relatively short time.
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